BACKGROUND: In squamous cell carcinoma of the head and neck (SCCHN), epidermal
growth factor receptor is expressed at very high levels. Hence, we have done this study to …

BACKGROUND AND PURPOSE: For locoregionally advanced HNSCC, chemoradiotherapy
with cisplatin or another platinum compound is considered as one of the standard treatment …

Purpose: To evaluate feasibility, safety and outcome of cetuximab concurrent with
radiotherapy in locally advanced head− neck cancer. Materials and Methods: Between …

Dual Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2
Inhibition in Squamous Cell Carcinoma of the Head and Neck; Is the Jury Still Out …

Purpose To determine the potential efficacy of combining cetuximab with chemotherapy in
patients with advanced nodal disease, we conducted a phase II trial with induction …

5513 Background: The goal of this study was to investigate the safety and efficacy of
cetuximab (Erbitux), an IgG1 monoclonal antibody targeting the EGFR, given in combination …

Purpose This multicenter phase II study was undertaken to define the efficacy and safety of
cetuximab, an antiepidermal growth factor receptor chimeric human and murine monoclonal …

Recently published evidence has shown an improvement in locoregional control and a
survival advantage in the treatment of squamous cell carcinomas of the head and neck …

Background The efficacy and safety of a novel combination of weekly paclitaxel and the
epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab for the first-line …

5505 Background: Patients with R&M SCCHN have a poor prognosis. Patients failing first-
line therapy have few therapeutic options. Cetuximab (Erbitux) is an IgG1 monoclonal …